Most of these genetic engineering approaches involve the removal of programmed cell death protein 1 (PD-1, PDCD1) from T cells, thus precluding its interaction with programmed death ligand 1 (PD-L1) on antigen-presenting and tumor cells. This evidence concerns the gene PDCD1 and neoplasm.